This research project aims to improve our understanding of preeclampsia, a condition that affects pregnant women and is characterized by high blood pressure and protein in the urine. It’s well-known that genetic factors play a role in preeclampsia, and this project will use data from the UK Biobank database to identify these genetic variants. We will conduct a genome-wide association study (GWAS), a method that allows us to find genetic variants associated with the condition. In addition, we will also use whole-genome sequencing and RNA-seq to get a detailed view of these genetic variants and how they are expressed in the body. To ensure the findings are robust and applicable in the real world, we will assemble a cohort of patients and validate the findings against this group. This step is crucial as it helps bridge the gap between statistical associations and clinical applicability. The next step involves constructing a predictive model using machine learning methods. Specifically, the team will apply random forest models, a powerful machine learning algorithm known for its ability to handle high-dimensional data and select predictive factors effectively. The ultimate goal is to develop a model that can predict the severity of preeclampsia for each patient, thereby optimizing treatment strategies. By accurately predicting the severity of preeclampsia, we can guide clinical decision-making and ensure that each patient receives the most appropriate and effective care. This personalized approach has the potential to improve patient outcomes significantly. In summary, this research project will provide important information about the genetic factors related to preeclampsia, helping to improve the diagnosis and treatment of pregnant women. It’s an exciting step forward in personalized medicine and has the potential to make a big difference in the lives of many women.
